Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 2, 2012, Pages 161-165

  Fortnum, H ^a   Lee, A J ^b   Rupnik, B ^c   Avery, A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

Adverse drug reactions; Patient reporting; Pharmacovigilance; Public awareness

Indexed keywords

ARTICLE; AWARENESS; DRUG SURVEILLANCE PROGRAM; EDUCATION; HEALTH SURVEY; HUMAN; INFORMATION SERVICE; INTERVIEW; POPULATION RESEARCH; QUESTIONNAIRE; SELF REPORT; SOCIAL BACKGROUND; UNITED KINGDOM;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; DATA COLLECTION; EDUCATIONAL STATUS; FEMALE; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; SEX FACTORS; YOUNG ADULT;

EID: 84858001707     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01273.x     Document Type: Article

References (16)

1. Moore TJ, Psaty BM, Furberg CD Time to act on drug safety. Journal of the American Medical Association, 1998;279:1571-1573. (Pubitemid 28233014)
2. Jarernsiripornkul N, Krska J, Capps P, Richards R, Lee A Patient reporting of potential adverse drug reactions: a methodological study. British Journal of Clinical Pharmacology, 2002;53:318-325. (Pubitemid 34226975)
3. van Grootheest K, de Graaf L, de Jongvan den Berg L Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Safety, 2003;26:211-217.
4. Ekins-Daukes S, Irvine D, Wise L, Fiddes S The Yellow Card Scheme: evaluation of reporting of suspected adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2006;15:S105.
5. Cumber SL, Heffer SJ, Gandhi S, Avery AJ The Yellow Card Scheme: experience of patient reporting of adverse drug reactions 5 years since launch. Pharmacoepidemiology & Drug Safety, 2010;19(Suppl. 1), S321.
6. AERS Reporting by Healthcare Providers and Consumers by Year. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Surveillance/AdverseDrugEffects/ucm070456.htm (accessed 20 August 2010).
7. Health Canada (2003) Public opinion survey on key issues pertaining to post-market surveillance of marketed health products in Canada. Final Report, POR# 298-02. Canada: Decima Research Institute.
8. Aagaard L, Lars Hougaard N, Ebba Holme H Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish Adverse Drug Reaction Database from 2004 to 2006. Drug Safety, 2009;32:1067-1074.
9. de Langen J, van Hunsel F, Passier A, de Jong-van den Berg L, van Grootheest K Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Safety, 2008;31:515-524. (Pubitemid 351693684)
10. McGuire T, Moses G What do consumers contribute to pharmacovigilance? Lessons from the AME line. In: Conference Proceedings, National Medicines Symposium, National Convention Centre, Canberra 7-9 June 2006. Available at: http://www.icms.com.au/nms2006/abstract/132.htm (accessed 20 August 2010).
11. Blenkinsopp A, Wilkie P, Wang M, Routledge PA Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. British Journal of Clinical Pharmacology, 2007;63:148-156. (Pubitemid 46072099)
12. Hazell L, Shakir SA Under-reporting of adverse drug reactions: a systematic review. Drug Safety, 2006;29:385-396.
13. National Statistics Opinions (Omnibus) Survey: User Guide. Available at: http://www.statistics.gov.uk/about/services/omnibus/downloads/User-Guide.pdf (accessed 20 August 2010).
14. Thomas K, Coleman P Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus survey. Journal of Public Health, 2004;26:152-157. (Pubitemid 39030850)
15. Avery A, Anderson C, Bond C et al. (2011) Evaluation of patient reporting to the yellow card scheme. Health Technology Assessment, in press.
16. McLernon D, Bond C, Lee A et al. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiology and Drug Safety, 2010;20:523-531.